"AreaCode","AreaName","CategoryAttribute","Denominator","Factor","HighestPriorityNotificationType","IndicatorCode","IndicatorName","IndicatorShortName","LowerConfidenceLimit","MetricCategoryName","MetricCategoryTypeName","NotificationCount","Numerator","TimePeriodName","UpperConfidenceLimit","Value","ValueNote"
"E54000040","Bath and North East Somerset, Swindon and Wiltshire","Persons",114680,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",45.16,"Persons","Sex",0,52125,"To March 2022",45.74,45.45,NA
"E54000024","Bedfordshire, Luton and Milton Keynes","Persons",99945,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.67,"Persons","Sex",0,49950,"To March 2022",50.29,49.98,NA
"E54000017","Birmingham and Solihull","Persons",131520,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",53.72,"Persons","Sex",0,71010,"To March 2022",54.26,53.99,NA
"E54000039","Bristol, North Somerset and South Gloucestershire","Persons",114185,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",44.21,"Persons","Sex",0,50805,"To March 2022",44.78,44.49,NA
"E54000044","Buckinghamshire, Oxfordshire and Berkshire West","Persons",198960,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",42.43,"Persons","Sex",0,84855,"To March 2022",42.87,42.65,NA
"E54000021","Cambridgeshire and Peterborough","Persons",96215,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",45.62,"Persons","Sex",0,44195,"To March 2022",46.25,45.93,NA
"E54000008","Cheshire and Merseyside","Persons",348095,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.21,"Persons","Sex",0,168395,"To March 2022",48.54,48.38,NA
"E54000036","Cornwall and the Isles of Scilly Health and Social Care Partnership","Persons",52465,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",45.35,"Persons","Sex",0,24015,"To March 2022",46.2,45.77,NA
"E54000018","Coventry and Warwickshire","Persons",118510,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",45.84,"Persons","Sex",0,54655,"To March 2022",46.4,46.12,NA
"E54000050","Cumbria and North East","Persons",421455,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",50.64,"Persons","Sex",0,214055,"To March 2022",50.94,50.79,NA
"E54000037","Devon","Persons",134680,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",45.3,"Persons","Sex",0,61360,"To March 2022",45.83,45.56,NA
"E54000041","Dorset","Persons",96945,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",42.21,"Persons","Sex",0,41220,"To March 2022",42.83,42.52,NA
"E54000029","East London Health and Care Partnership","Persons",201230,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",54.49,"Persons","Sex",0,110095,"To March 2022",54.93,54.71,NA
"E54000034","Frimley Health and Care ICS","Persons",77530,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.32,"Persons","Sex",0,37735,"To March 2022",49.02,48.67,NA
"E54000043","Gloucestershire","Persons",83000,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",41.51,"Persons","Sex",0,34725,"To March 2022",42.18,41.84,NA
"E54000007","Greater Manchester Health and Social Care Partnership","Persons",349080,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.21,"Persons","Sex",0,182820,"To March 2022",52.54,52.37,NA
"E54000042","Hampshire and the Isle of Wight","Persons",208905,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",42.33,"Persons","Sex",0,88875,"To March 2022",42.75,42.54,NA
"E54000048","Healthier Lancashire and South Cumbria","Persons",236330,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",47.69,"Persons","Sex",0,113190,"To March 2022",48.1,47.9,NA
"E54000019","Herefordshire and Worcestershire","Persons",117165,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",41.47,"Persons","Sex",0,48920,"To March 2022",42.03,41.75,NA
"E54000025","Hertfordshire and West Essex","Persons",167790,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.99,"Persons","Sex",0,84285,"To March 2022",50.47,50.23,NA
"E54000051","Humber, Coast and Vale","Persons",218360,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.23,"Persons","Sex",0,101400,"To March 2022",46.65,46.44,NA
"E54000012","Joined Up Care Derbyshire","Persons",145350,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",45.46,"Persons","Sex",0,66450,"To March 2022",45.97,45.72,NA
"E54000032","Kent and Medway","Persons",235305,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",45.39,"Persons","Sex",0,107275,"To March 2022",45.79,45.59,NA
"E54000015","Leicester, Leicestershire and Rutland","Persons",142935,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.56,"Persons","Sex",0,71215,"To March 2022",50.08,49.82,NA
"E54000013","Lincolnshire","Persons",113710,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",47.09,"Persons","Sex",0,53875,"To March 2022",47.67,47.38,NA
"E54000026","Mid and South Essex","Persons",134495,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.05,"Persons","Sex",0,66325,"To March 2022",49.58,49.32,NA
"E54000022","Norfolk and Waveney Health and Care Partnership","Persons",150095,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.72,"Persons","Sex",0,70505,"To March 2022",47.23,46.98,NA
"E54000028","North London Partners in Health and Care","Persons",143235,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.57,"Persons","Sex",0,71380,"To March 2022",50.09,49.83,NA
"E54000027","North West London Health and Care Partnership","Persons",231420,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",53.4,"Persons","Sex",0,124045,"To March 2022",53.8,53.6,NA
"E54000020","Northamptonshire","Persons",85555,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51,"Persons","Sex",0,43920,"To March 2022",51.67,51.34,NA
"E54000014","Nottingham and Nottinghamshire Health and Care","Persons",131285,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.16,"Persons","Sex",0,63585,"To March 2022",48.7,48.43,NA
"E54000030","Our Healthier South East London","Persons",167315,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.78,"Persons","Sex",0,78675,"To March 2022",47.26,47.02,NA
"E54000011","Shropshire and Telford and Wrekin","Persons",71120,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",43.28,"Persons","Sex",0,31045,"To March 2022",44.01,43.65,NA
"E54000038","Somerset","Persons",86525,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",43.84,"Persons","Sex",0,38220,"To March 2022",44.5,44.17,NA
"E54000031","South West London Health and Care Partnership","Persons",144040,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",45.64,"Persons","Sex",0,66110,"To March 2022",46.16,45.9,NA
"E54000009","South Yorkshire and Bassetlaw","Persons",191300,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",54.68,"Persons","Sex",0,105035,"To March 2022",55.13,54.91,NA
"E54000010","Staffordshire and Stoke on Trent","Persons",159320,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",47.77,"Persons","Sex",0,76500,"To March 2022",48.26,48.02,NA
"E54000023","Suffolk and North East Essex","Persons",136765,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",45.51,"Persons","Sex",0,62600,"To March 2022",46.04,45.77,NA
"E54000052","Surrey Heartlands Health and Care Partnership","Persons",106155,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",43.4,"Persons","Sex",0,46385,"To March 2022",44,43.7,NA
"E54000053","Sussex and East Surrey Health and Care Partnership","Persons",212840,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",44.18,"Persons","Sex",0,94480,"To March 2022",44.6,44.39,NA
"E54000016","The Black Country and West Birmingham","Persons",173650,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",53.37,"Persons","Sex",0,93090,"To March 2022",53.84,53.61,NA
"E54000054","West Yorkshire and Harrogate (Health and Care Partnership)","Persons",284340,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",53.15,"Persons","Sex",0,151645,"To March 2022",53.51,53.33,NA
"E54000040","NHS Bath and North East Somerset, Swindon and Wiltshire Integrated Care Board","Persons",115850,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",43.59,"Persons","Sex",0,50825,"To June 2022",44.16,43.87,NA
"E54000024","NHS Bedfordshire, Luton and Milton Keynes Integrated Care Board","Persons",101540,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",50.2,"Persons","Sex",0,51285,"To June 2022",50.81,50.51,NA
"E54000055","NHS Birmingham and Solihull Integrated Care Board","Persons",160345,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",54.35,"Persons","Sex",0,87535,"To June 2022",54.84,54.59,NA
"E54000062","NHS Black Country Integrated Care Board","Persons",157595,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",53.4,"Persons","Sex",0,84545,"To June 2022",53.89,53.65,NA
"E54000039","NHS Bristol, North Somerset and South Gloucestershire Integrated Care Board","Persons",114480,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",44.86,"Persons","Sex",0,51690,"To June 2022",45.44,45.15,NA
"E54000044","NHS Buckinghamshire, Oxfordshire and Berkshire West Integrated Care Board","Persons",202700,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",43.18,"Persons","Sex",0,87955,"To June 2022",43.61,43.39,NA
"E54000056","NHS Cambridgeshire and Peterborough Integrated Care Board","Persons",95905,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.39,"Persons","Sex",0,44790,"To June 2022",47.02,46.7,NA
"E54000008","NHS Cheshire and Merseyside Integrated Care Board","Persons",353465,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.84,"Persons","Sex",0,173215,"To June 2022",49.17,49,NA
"E54000036","NHS Cornwall and the Isles of Scilly Integrated Care Board","Persons",53705,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.04,"Persons","Sex",0,24955,"To June 2022",46.89,46.47,NA
"E54000018","NHS Coventry and Warwickshire Integrated Care Board","Persons",122590,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.34,"Persons","Sex",0,57150,"To June 2022",46.9,46.62,NA
"E54000058","NHS Derby and Derbyshire Integrated Care Board","Persons",149940,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.35,"Persons","Sex",0,69875,"To June 2022",46.85,46.6,NA
"E54000037","NHS Devon Integrated Care Board","Persons",136435,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",45.98,"Persons","Sex",0,63095,"To June 2022",46.51,46.25,NA
"E54000041","NHS Dorset Integrated Care Board","Persons",97615,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",43.23,"Persons","Sex",0,42505,"To June 2022",43.86,43.54,NA
"E54000034","NHS Frimley Integrated Care Board","Persons",79240,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.13,"Persons","Sex",0,39205,"To June 2022",49.82,49.47,NA
"E54000043","NHS Gloucestershire Integrated Care Board","Persons",83790,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",42.71,"Persons","Sex",0,36065,"To June 2022",43.38,43.04,NA
"E54000057","NHS Greater Manchester Integrated Care Board","Persons",297730,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",54.3,"Persons","Sex",0,162205,"To June 2022",54.66,54.48,NA
"E54000042","Nhs Hampshire And Isle Of Wight Integrated Care Board","Persons",214795,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",42.81,"Persons","Sex",0,92410,"To June 2022",43.23,43.02,NA
"E54000019","NHS Herefordshire and Worcestershire Integrated Care Board","Persons",119930,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",42.18,"Persons","Sex",0,50920,"To June 2022",42.74,42.46,NA
"E54000025","NHS Hertfordshire and West Essex Integrated Care Board","Persons",172485,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",50.21,"Persons","Sex",0,87015,"To June 2022",50.68,50.45,NA
"E54000051","NHS Humber and North Yorkshire Integrated Care Board","Persons",219965,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.85,"Persons","Sex",0,103520,"To June 2022",47.27,47.06,NA
"E54000032","NHS Kent and Medway Integrated Care Board","Persons",240700,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",45.77,"Persons","Sex",0,110645,"To June 2022",46.17,45.97,NA
"E54000048","NHS Lancashire and South Cumbria Integrated Care Board","Persons",240165,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.13,"Persons","Sex",0,116075,"To June 2022",48.53,48.33,NA
"E54000015","NHS Leicester, Leicestershire and Rutland Integrated Care Board","Persons",143795,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.88,"Persons","Sex",0,72095,"To June 2022",50.39,50.14,NA
"E54000013","NHS Lincolnshire Integrated Care Board","Persons",118520,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.16,"Persons","Sex",0,57420,"To June 2022",48.73,48.45,NA
"E54000026","NHS Mid and South Essex Integrated Care Board","Persons",136145,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.69,"Persons","Sex",0,68005,"To June 2022",50.22,49.95,NA
"E54000022","Nhs Norfolk And Waveney Integrated Care Board","Persons",151255,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",47.54,"Persons","Sex",0,72290,"To June 2022",48.04,47.79,NA
"E54000028","NHS North Central London Integrated Care Board","Persons",151880,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.91,"Persons","Sex",0,76180,"To June 2022",50.41,50.16,NA
"E54000050","NHS North East and North Cumbria Integrated Care Board","Persons",424050,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.42,"Persons","Sex",0,218670,"To June 2022",51.72,51.57,NA
"E54000029","NHS North East London Integrated Care Board","Persons",203885,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",54.19,"Persons","Sex",0,110925,"To June 2022",54.62,54.4,NA
"E54000027","NHS North West London Integrated Care Board","Persons",238295,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",53.43,"Persons","Sex",0,127795,"To June 2022",53.83,53.63,NA
"E54000059","NHS Northamptonshire Integrated Care Board","Persons",89290,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.39,"Persons","Sex",0,46180,"To June 2022",52.05,51.72,NA
"E54000060","NHS Nottingham and Nottinghamshire Integrated Care Board","Persons",150865,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.81,"Persons","Sex",0,74020,"To June 2022",49.31,49.06,NA
"E54000011","NHS Shropshire, Telford and Wrekin Integrated Care Board","Persons",75385,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",44.54,"Persons","Sex",0,33845,"To June 2022",45.25,44.89,NA
"E54000038","NHS Somerset Integrated Care Board","Persons",86050,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",44.51,"Persons","Sex",0,38590,"To June 2022",45.18,44.85,NA
"E54000030","NHS South East London Integrated Care Board","Persons",163405,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",47.84,"Persons","Sex",0,78565,"To June 2022",48.32,48.08,NA
"E54000031","NHS South West London Integrated Care Board","Persons",145160,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.34,"Persons","Sex",0,67635,"To June 2022",46.85,46.59,NA
"E54000061","NHS South Yorkshire Integrated Care Board","Persons",177110,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",55.58,"Persons","Sex",0,98840,"To June 2022",56.04,55.81,NA
"E54000010","NHS Staffordshire and Stoke-on-Trent Integrated Care Board","Persons",159280,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.32,"Persons","Sex",0,77350,"To June 2022",48.81,48.56,NA
"E54000023","NHS Suffolk and North East Essex Integrated Care Board","Persons",140935,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.29,"Persons","Sex",0,65610,"To June 2022",46.81,46.55,NA
"E54000052","NHS Surrey Heartlands Integrated Care Board","Persons",107180,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",43.99,"Persons","Sex",0,47465,"To June 2022",44.58,44.28,NA
"E54000053","NHS Sussex Integrated Care Board","Persons",216595,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",44.76,"Persons","Sex",0,97400,"To June 2022",45.18,44.97,NA
"E54000054","NHS West Yorkshire Integrated Care Board","Persons",290015,1,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",53.6,"Persons","Sex",0,155970,"To June 2022",53.96,53.78,NA
"E54000040","NHS Bath and North East Somerset, Swindon and Wiltshire Integrated Care Board","Persons",116555,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",42.92,"Persons","Sex",0,50355,"To September 2022",43.49,43.2,NA
"E54000024","NHS Bedfordshire, Luton and Milton Keynes Integrated Care Board","Persons",103085,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",50.97,"Persons","Sex",0,52860,"To September 2022",51.58,51.28,NA
"E54000055","NHS Birmingham and Solihull Integrated Care Board","Persons",161800,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",54.85,"Persons","Sex",0,89140,"To September 2022",55.33,55.09,NA
"E54000062","NHS Black Country Integrated Care Board","Persons",157275,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",54.08,"Persons","Sex",0,85445,"To September 2022",54.57,54.33,NA
"E54000039","NHS Bristol, North Somerset and South Gloucestershire Integrated Care Board","Persons",114895,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",45.85,"Persons","Sex",0,53010,"To September 2022",46.42,46.14,NA
"E54000044","NHS Buckinghamshire, Oxfordshire and Berkshire West Integrated Care Board","Persons",204470,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",43.81,"Persons","Sex",0,90025,"To September 2022",44.24,44.03,NA
"E54000056","NHS Cambridgeshire and Peterborough Integrated Care Board","Persons",96555,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",47.11,"Persons","Sex",0,45795,"To September 2022",47.74,47.43,NA
"E54000008","NHS Cheshire and Merseyside Integrated Care Board","Persons",352075,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.57,"Persons","Sex",0,175105,"To September 2022",49.9,49.73,NA
"E54000036","NHS Cornwall and the Isles of Scilly Integrated Care Board","Persons",55620,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.69,"Persons","Sex",0,26200,"To September 2022",47.52,47.11,NA
"E54000018","NHS Coventry and Warwickshire Integrated Care Board","Persons",123650,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",47.14,"Persons","Sex",0,58640,"To September 2022",47.7,47.42,NA
"E54000058","NHS Derby and Derbyshire Integrated Care Board","Persons",152465,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",47.16,"Persons","Sex",0,72285,"To September 2022",47.66,47.41,NA
"E54000037","NHS Devon Integrated Care Board","Persons",137645,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.71,"Persons","Sex",0,64660,"To September 2022",47.24,46.98,NA
"E54000041","NHS Dorset Integrated Care Board","Persons",98415,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",43.89,"Persons","Sex",0,43500,"To September 2022",44.51,44.2,NA
"E54000034","NHS Frimley Integrated Care Board","Persons",78545,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.69,"Persons","Sex",0,39300,"To September 2022",50.39,50.04,NA
"E54000043","NHS Gloucestershire Integrated Care Board","Persons",84705,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",44.01,"Persons","Sex",0,37560,"To September 2022",44.68,44.34,NA
"E54000057","NHS Greater Manchester Integrated Care Board","Persons",358770,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.29,"Persons","Sex",0,188185,"To September 2022",52.62,52.45,NA
"E54000042","Nhs Hampshire And Isle Of Wight Integrated Care Board","Persons",215805,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",43.35,"Persons","Sex",0,94010,"To September 2022",43.77,43.56,NA
"E54000019","NHS Herefordshire and Worcestershire Integrated Care Board","Persons",120900,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",43.01,"Persons","Sex",0,52340,"To September 2022",43.57,43.29,NA
"E54000025","NHS Hertfordshire and West Essex Integrated Care Board","Persons",174130,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",50.79,"Persons","Sex",0,88855,"To September 2022",51.26,51.03,NA
"E54000051","NHS Humber and North Yorkshire Integrated Care Board","Persons",221565,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",47.59,"Persons","Sex",0,105905,"To September 2022",48.01,47.8,NA
"E54000032","NHS Kent and Medway Integrated Care Board","Persons",242595,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.33,"Persons","Sex",0,112875,"To September 2022",46.73,46.53,NA
"E54000048","NHS Lancashire and South Cumbria Integrated Care Board","Persons",241355,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.81,"Persons","Sex",0,118280,"To September 2022",49.21,49.01,NA
"E54000015","NHS Leicester, Leicestershire and Rutland Integrated Care Board","Persons",146425,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",50.61,"Persons","Sex",0,74485,"To September 2022",51.12,50.87,NA
"E54000013","NHS Lincolnshire Integrated Care Board","Persons",119855,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.99,"Persons","Sex",0,59055,"To September 2022",49.55,49.27,NA
"E54000026","NHS Mid and South Essex Integrated Care Board","Persons",137370,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",50.27,"Persons","Sex",0,69420,"To September 2022",50.8,50.54,NA
"E54000022","Nhs Norfolk And Waveney Integrated Care Board","Persons",152360,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.32,"Persons","Sex",0,74005,"To September 2022",48.82,48.57,NA
"E54000028","NHS North Central London Integrated Care Board","Persons",154335,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",50.11,"Persons","Sex",0,77725,"To September 2022",50.61,50.36,NA
"E54000050","NHS North East and North Cumbria Integrated Care Board","Persons",426105,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.31,"Persons","Sex",0,223530,"To September 2022",52.61,52.46,NA
"E54000029","NHS North East London Integrated Care Board","Persons",210265,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",54.15,"Persons","Sex",0,114305,"To September 2022",54.57,54.36,NA
"E54000027","NHS North West London Integrated Care Board","Persons",238790,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",53.87,"Persons","Sex",0,129110,"To September 2022",54.27,54.07,NA
"E54000059","NHS Northamptonshire Integrated Care Board","Persons",89780,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.23,"Persons","Sex",0,47185,"To September 2022",52.88,52.56,NA
"E54000060","NHS Nottingham and Nottinghamshire Integrated Care Board","Persons",152030,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.5,"Persons","Sex",0,75640,"To September 2022",50,49.75,NA
"E54000011","NHS Shropshire, Telford and Wrekin Integrated Care Board","Persons",76095,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",45.49,"Persons","Sex",0,34885,"To September 2022",46.2,45.84,NA
"E54000038","NHS Somerset Integrated Care Board","Persons",87485,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",44.36,"Persons","Sex",0,39100,"To September 2022",45.02,44.69,NA
"E54000030","NHS South East London Integrated Care Board","Persons",170105,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",47.69,"Persons","Sex",0,81530,"To September 2022",48.17,47.93,NA
"E54000031","NHS South West London Integrated Care Board","Persons",147925,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.66,"Persons","Sex",0,69395,"To September 2022",47.17,46.91,NA
"E54000061","NHS South Yorkshire Integrated Care Board","Persons",177085,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",56.42,"Persons","Sex",0,100325,"To September 2022",56.88,56.65,NA
"E54000010","NHS Staffordshire and Stoke-on-Trent Integrated Care Board","Persons",159735,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.14,"Persons","Sex",0,78885,"To September 2022",49.63,49.38,NA
"E54000023","NHS Suffolk and North East Essex Integrated Care Board","Persons",142625,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.99,"Persons","Sex",0,67395,"To September 2022",47.51,47.25,NA
"E54000052","NHS Surrey Heartlands Integrated Care Board","Persons",108435,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",44.53,"Persons","Sex",0,48610,"To September 2022",45.12,44.83,NA
"E54000053","NHS Sussex Integrated Care Board","Persons",217460,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",45.52,"Persons","Sex",0,99450,"To September 2022",45.94,45.73,NA
"E54000054","NHS West Yorkshire Integrated Care Board","Persons",292905,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",54.27,"Persons","Sex",0,159500,"To September 2022",54.64,54.46,NA
"E54000040","NHS Bath and North East Somerset, Swindon and Wiltshire Integrated Care Board","Persons",118125,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",43.46,"Persons","Sex",0,51665,"To December 2022",44.02,43.74,NA
"E54000024","NHS Bedfordshire, Luton and Milton Keynes Integrated Care Board","Persons",104845,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.63,"Persons","Sex",0,54445,"To December 2022",52.23,51.93,NA
"E54000055","NHS Birmingham and Solihull Integrated Care Board","Persons",166820,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",55.28,"Persons","Sex",0,92620,"To December 2022",55.76,55.52,NA
"E54000062","NHS Black Country Integrated Care Board","Persons",158700,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",54.62,"Persons","Sex",0,87080,"To December 2022",55.11,54.87,NA
"E54000039","NHS Bristol, North Somerset and South Gloucestershire Integrated Care Board","Persons",113420,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.75,"Persons","Sex",0,53355,"To December 2022",47.33,47.04,NA
"E54000044","NHS Buckinghamshire, Oxfordshire and Berkshire West Integrated Care Board","Persons",204070,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",44.49,"Persons","Sex",0,91240,"To December 2022",44.93,44.71,NA
"E54000056","NHS Cambridgeshire and Peterborough Integrated Care Board","Persons",98550,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",47.79,"Persons","Sex",0,47405,"To December 2022",48.41,48.1,NA
"E54000008","NHS Cheshire and Merseyside Integrated Care Board","Persons",353365,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.99,"Persons","Sex",0,177240,"To December 2022",50.32,50.16,NA
"E54000036","NHS Cornwall and the Isles of Scilly Integrated Care Board","Persons",56525,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",47.13,"Persons","Sex",0,26875,"To December 2022",47.96,47.55,NA
"E54000018","NHS Coventry and Warwickshire Integrated Care Board","Persons",120875,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",47.39,"Persons","Sex",0,57630,"To December 2022",47.96,47.68,NA
"E54000058","NHS Derby and Derbyshire Integrated Care Board","Persons",153085,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",47.83,"Persons","Sex",0,73600,"To December 2022",48.33,48.08,NA
"E54000037","NHS Devon Integrated Care Board","Persons",137005,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",47.42,"Persons","Sex",0,65325,"To December 2022",47.94,47.68,NA
"E54000041","NHS Dorset Integrated Care Board","Persons",98745,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",44.57,"Persons","Sex",0,44320,"To December 2022",45.19,44.88,NA
"E54000034","NHS Frimley Integrated Care Board","Persons",78580,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.96,"Persons","Sex",0,39535,"To December 2022",50.66,50.31,NA
"E54000043","NHS Gloucestershire Integrated Care Board","Persons",85785,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",45.03,"Persons","Sex",0,38915,"To December 2022",45.7,45.37,NA
"E54000057","NHS Greater Manchester Integrated Care Board","Persons",357890,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.5,"Persons","Sex",0,188490,"To December 2022",52.83,52.67,NA
"E54000042","Nhs Hampshire And Isle Of Wight Integrated Care Board","Persons",218515,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",43.85,"Persons","Sex",0,96270,"To December 2022",44.27,44.06,NA
"E54000019","NHS Herefordshire and Worcestershire Integrated Care Board","Persons",115365,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",44.19,"Persons","Sex",0,51305,"To December 2022",44.76,44.47,NA
"E54000025","NHS Hertfordshire and West Essex Integrated Care Board","Persons",176515,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.24,"Persons","Sex",0,90855,"To December 2022",51.71,51.47,NA
"E54000051","NHS Humber and North Yorkshire Integrated Care Board","Persons",223245,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.23,"Persons","Sex",0,108140,"To December 2022",48.65,48.44,NA
"E54000032","NHS Kent and Medway Integrated Care Board","Persons",246955,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.76,"Persons","Sex",0,115955,"To December 2022",47.15,46.95,NA
"E54000048","NHS Lancashire and South Cumbria Integrated Care Board","Persons",233510,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.41,"Persons","Sex",0,115860,"To December 2022",49.82,49.62,NA
"E54000015","NHS Leicester, Leicestershire and Rutland Integrated Care Board","Persons",149150,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.2,"Persons","Sex",0,76740,"To December 2022",51.7,51.45,NA
"E54000013","NHS Lincolnshire Integrated Care Board","Persons",118340,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",50.06,"Persons","Sex",0,59580,"To December 2022",50.63,50.35,NA
"E54000026","NHS Mid and South Essex Integrated Care Board","Persons",138745,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",50.83,"Persons","Sex",0,70890,"To December 2022",51.36,51.1,NA
"E54000022","Nhs Norfolk And Waveney Integrated Care Board","Persons",154470,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.89,"Persons","Sex",0,75905,"To December 2022",49.39,49.14,NA
"E54000028","NHS North Central London Integrated Care Board","Persons",155365,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",50.54,"Persons","Sex",0,78910,"To December 2022",51.04,50.79,NA
"E54000050","NHS North East and North Cumbria Integrated Care Board","Persons",433985,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.83,"Persons","Sex",0,229925,"To December 2022",53.13,52.98,NA
"E54000029","NHS North East London Integrated Care Board","Persons",211515,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",54.83,"Persons","Sex",0,116415,"To December 2022",55.25,55.04,NA
"E54000027","NHS North West London Integrated Care Board","Persons",243185,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",54.13,"Persons","Sex",0,132120,"To December 2022",54.53,54.33,NA
"E54000059","NHS Northamptonshire Integrated Care Board","Persons",92200,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.69,"Persons","Sex",0,48880,"To December 2022",53.34,53.01,NA
"E54000060","NHS Nottingham and Nottinghamshire Integrated Care Board","Persons",152945,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",50.04,"Persons","Sex",0,76920,"To December 2022",50.54,50.29,NA
"E54000011","NHS Shropshire, Telford and Wrekin Integrated Care Board","Persons",76640,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.32,"Persons","Sex",0,35775,"To December 2022",47.03,46.68,NA
"E54000038","NHS Somerset Integrated Care Board","Persons",85570,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",45.48,"Persons","Sex",0,39205,"To December 2022",46.15,45.82,NA
"E54000030","NHS South East London Integrated Care Board","Persons",183410,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.8,"Persons","Sex",0,86260,"To December 2022",47.26,47.03,NA
"E54000031","NHS South West London Integrated Care Board","Persons",149825,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",47.08,"Persons","Sex",0,70915,"To December 2022",47.58,47.33,NA
"E54000061","NHS South Yorkshire Integrated Care Board","Persons",178625,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",56.98,"Persons","Sex",0,102195,"To December 2022",57.44,57.21,NA
"E54000010","NHS Staffordshire and Stoke-on-Trent Integrated Care Board","Persons",157695,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",50.24,"Persons","Sex",0,79615,"To December 2022",50.73,50.49,NA
"E54000023","NHS Suffolk and North East Essex Integrated Care Board","Persons",145500,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",47.63,"Persons","Sex",0,69680,"To December 2022",48.15,47.89,NA
"E54000052","NHS Surrey Heartlands Integrated Care Board","Persons",110700,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",45.12,"Persons","Sex",0,50275,"To December 2022",45.71,45.42,NA
"E54000053","NHS Sussex Integrated Care Board","Persons",226955,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.07,"Persons","Sex",0,105030,"To December 2022",46.48,46.28,NA
"E54000054","NHS West Yorkshire Integrated Care Board","Persons",297350,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",54.7,"Persons","Sex",0,163190,"To December 2022",55.06,54.88,NA
"E54000040","NHS Bath and North East Somerset, Swindon and Wiltshire Integrated Care Board","Persons",118080,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",44.76,"Persons","Sex",0,53185,"To March 2023",45.33,45.04,NA
"E54000024","NHS Bedfordshire, Luton and Milton Keynes Integrated Care Board","Persons",106120,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",53.02,"Persons","Sex",0,56580,"To March 2023",53.62,53.32,NA
"E54000055","NHS Birmingham and Solihull Integrated Care Board","Persons",167080,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",56.79,"Persons","Sex",0,95285,"To March 2023",57.27,57.03,NA
"E54000062","NHS Black Country Integrated Care Board","Persons",160320,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",55.85,"Persons","Sex",0,89930,"To March 2023",56.34,56.09,NA
"E54000039","NHS Bristol, North Somerset and South Gloucestershire Integrated Care Board","Persons",115570,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.3,"Persons","Sex",0,56155,"To March 2023",48.88,48.59,NA
"E54000044","NHS Buckinghamshire, Oxfordshire and Berkshire West Integrated Care Board","Persons",208210,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",45.78,"Persons","Sex",0,95770,"To March 2023",46.21,46,NA
"E54000056","NHS Cambridgeshire and Peterborough Integrated Care Board","Persons",92640,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.93,"Persons","Sex",0,45630,"To March 2023",49.58,49.26,NA
"E54000008","NHS Cheshire and Merseyside Integrated Care Board","Persons",362040,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.08,"Persons","Sex",0,185520,"To March 2023",51.4,51.24,NA
"E54000036","NHS Cornwall and the Isles of Scilly Integrated Care Board","Persons",58555,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.5,"Persons","Sex",0,28635,"To March 2023",49.3,48.9,NA
"E54000018","NHS Coventry and Warwickshire Integrated Care Board","Persons",127925,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.49,"Persons","Sex",0,62385,"To March 2023",49.04,48.77,NA
"E54000058","NHS Derby and Derbyshire Integrated Care Board","Persons",153680,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.01,"Persons","Sex",0,75700,"To March 2023",49.51,49.26,NA
"E54000037","NHS Devon Integrated Care Board","Persons",138665,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.99,"Persons","Sex",0,68300,"To March 2023",49.52,49.26,NA
"E54000041","NHS Dorset Integrated Care Board","Persons",99315,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",45.97,"Persons","Sex",0,45965,"To March 2023",46.59,46.28,NA
"E54000034","NHS Frimley Integrated Care Board","Persons",82325,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.21,"Persons","Sex",0,42435,"To March 2023",51.89,51.55,NA
"E54000043","NHS Gloucestershire Integrated Care Board","Persons",87160,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.53,"Persons","Sex",0,40840,"To March 2023",47.19,46.86,NA
"E54000057","NHS Greater Manchester Integrated Care Board","Persons",373845,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",53.94,"Persons","Sex",0,202250,"To March 2023",54.26,54.1,NA
"E54000042","Nhs Hampshire And Isle Of Wight Integrated Care Board","Persons",218185,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",45.07,"Persons","Sex",0,98800,"To March 2023",45.49,45.28,NA
"E54000019","NHS Herefordshire and Worcestershire Integrated Care Board","Persons",123445,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",45.62,"Persons","Sex",0,56665,"To March 2023",46.18,45.9,NA
"E54000025","NHS Hertfordshire and West Essex Integrated Care Board","Persons",177125,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.24,"Persons","Sex",0,92940,"To March 2023",52.7,52.47,NA
"E54000051","NHS Humber and North Yorkshire Integrated Care Board","Persons",225410,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.56,"Persons","Sex",0,112175,"To March 2023",49.97,49.77,NA
"E54000032","NHS Kent and Medway Integrated Care Board","Persons",251105,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.22,"Persons","Sex",0,121565,"To March 2023",48.61,48.41,NA
"E54000048","NHS Lancashire and South Cumbria Integrated Care Board","Persons",248900,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",50.54,"Persons","Sex",0,126280,"To March 2023",50.93,50.74,NA
"E54000015","NHS Leicester, Leicestershire and Rutland Integrated Care Board","Persons",147875,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.34,"Persons","Sex",0,77775,"To March 2023",52.85,52.6,NA
"E54000013","NHS Lincolnshire Integrated Care Board","Persons",121300,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.06,"Persons","Sex",0,62280,"To March 2023",51.62,51.34,NA
"E54000026","NHS Mid and South Essex Integrated Care Board","Persons",139975,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.82,"Persons","Sex",0,72905,"To March 2023",52.35,52.09,NA
"E54000022","Nhs Norfolk And Waveney Integrated Care Board","Persons",154755,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.75,"Persons","Sex",0,77385,"To March 2023",50.25,50,NA
"E54000028","NHS North Central London Integrated Care Board","Persons",154830,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.99,"Persons","Sex",0,80880,"To March 2023",52.49,52.24,NA
"E54000050","NHS North East and North Cumbria Integrated Care Board","Persons",436530,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",54.23,"Persons","Sex",0,237360,"To March 2023",54.52,54.37,NA
"E54000029","NHS North East London Integrated Care Board","Persons",216080,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",55.92,"Persons","Sex",0,121275,"To March 2023",56.33,56.13,NA
"E54000027","NHS North West London Integrated Care Board","Persons",240945,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",55.31,"Persons","Sex",0,133750,"To March 2023",55.71,55.51,NA
"E54000059","NHS Northamptonshire Integrated Care Board","Persons",92675,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",54.15,"Persons","Sex",0,50480,"To March 2023",54.79,54.47,NA
"E54000060","NHS Nottingham and Nottinghamshire Integrated Care Board","Persons",153960,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.18,"Persons","Sex",0,79185,"To March 2023",51.68,51.43,NA
"E54000011","NHS Shropshire, Telford and Wrekin Integrated Care Board","Persons",77200,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",47.6,"Persons","Sex",0,37020,"To March 2023",48.31,47.95,NA
"E54000038","NHS Somerset Integrated Care Board","Persons",89005,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.26,"Persons","Sex",0,41460,"To March 2023",46.91,46.58,NA
"E54000030","NHS South East London Integrated Care Board","Persons",184705,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.2,"Persons","Sex",0,89445,"To March 2023",48.65,48.43,NA
"E54000031","NHS South West London Integrated Care Board","Persons",150720,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.4,"Persons","Sex",0,73325,"To March 2023",48.9,48.65,NA
"E54000061","NHS South Yorkshire Integrated Care Board","Persons",178510,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",58.27,"Persons","Sex",0,104420,"To March 2023",58.72,58.5,NA
"E54000010","NHS Staffordshire and Stoke-on-Trent Integrated Care Board","Persons",161810,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.43,"Persons","Sex",0,83610,"To March 2023",51.92,51.67,NA
"E54000023","NHS Suffolk and North East Essex Integrated Care Board","Persons",146720,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.7,"Persons","Sex",0,71825,"To March 2023",49.21,48.95,NA
"E54000052","NHS Surrey Heartlands Integrated Care Board","Persons",112035,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.3,"Persons","Sex",0,52200,"To March 2023",46.89,46.59,NA
"E54000053","NHS Sussex Integrated Care Board","Persons",229345,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",47.45,"Persons","Sex",0,109300,"To March 2023",47.86,47.66,NA
"E54000054","NHS West Yorkshire Integrated Care Board","Persons",298565,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",55.59,"Persons","Sex",0,166495,"To March 2023",55.94,55.77,NA
"E54000040","NHS Bath and North East Somerset, Swindon and Wiltshire Integrated Care Board","Persons",122220,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",45.64,"Persons","Sex",0,56125,"To June 2023",46.2,45.92,NA
"E54000024","NHS Bedfordshire, Luton and Milton Keynes Integrated Care Board","Persons",108860,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",53.85,"Persons","Sex",0,58945,"To June 2023",54.44,54.15,NA
"E54000055","NHS Birmingham and Solihull Integrated Care Board","Persons",172090,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",56.89,"Persons","Sex",0,98300,"To June 2023",57.35,57.12,NA
"E54000062","NHS Black Country Integrated Care Board","Persons",165310,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",55.89,"Persons","Sex",0,92790,"To June 2023",56.37,56.13,NA
"E54000039","NHS Bristol, North Somerset and South Gloucestershire Integrated Care Board","Persons",117415,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.31,"Persons","Sex",0,58225,"To June 2023",49.88,49.59,NA
"E54000044","NHS Buckinghamshire, Oxfordshire and Berkshire West Integrated Care Board","Persons",213115,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.52,"Persons","Sex",0,99595,"To June 2023",46.94,46.73,NA
"E54000056","NHS Cambridgeshire and Peterborough Integrated Care Board","Persons",102350,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.72,"Persons","Sex",0,51200,"To June 2023",50.33,50.03,NA
"E54000008","NHS Cheshire and Merseyside Integrated Care Board","Persons",374310,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.81,"Persons","Sex",0,194530,"To June 2023",52.13,51.97,NA
"E54000036","NHS Cornwall and the Isles of Scilly Integrated Care Board","Persons",61290,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.25,"Persons","Sex",0,30430,"To June 2023",50.04,49.65,NA
"E54000018","NHS Coventry and Warwickshire Integrated Care Board","Persons",130930,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.01,"Persons","Sex",0,64520,"To June 2023",49.55,49.28,NA
"E54000058","NHS Derby and Derbyshire Integrated Care Board","Persons",156310,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.98,"Persons","Sex",0,78510,"To June 2023",50.47,50.23,NA
"E54000037","NHS Devon Integrated Care Board","Persons",143825,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.88,"Persons","Sex",0,72115,"To June 2023",50.4,50.14,NA
"E54000041","NHS Dorset Integrated Care Board","Persons",101190,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.83,"Persons","Sex",0,47705,"To June 2023",47.45,47.14,NA
"E54000034","NHS Frimley Integrated Care Board","Persons",83205,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.72,"Persons","Sex",0,43315,"To June 2023",52.39,52.06,NA
"E54000043","NHS Gloucestershire Integrated Care Board","Persons",89370,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",47.62,"Persons","Sex",0,42855,"To June 2023",48.28,47.95,NA
"E54000057","NHS Greater Manchester Integrated Care Board","Persons",383165,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",54.57,"Persons","Sex",0,209710,"To June 2023",54.89,54.73,NA
"E54000042","Nhs Hampshire And Isle Of Wight Integrated Care Board","Persons",225780,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",45.89,"Persons","Sex",0,104065,"To June 2023",46.3,46.09,NA
"E54000019","NHS Herefordshire and Worcestershire Integrated Care Board","Persons",127085,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.6,"Persons","Sex",0,59570,"To June 2023",47.15,46.87,NA
"E54000025","NHS Hertfordshire and West Essex Integrated Care Board","Persons",183095,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.89,"Persons","Sex",0,97260,"To June 2023",53.35,53.12,NA
"E54000051","NHS Humber and North Yorkshire Integrated Care Board","Persons",230605,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",50.46,"Persons","Sex",0,116840,"To June 2023",50.87,50.67,NA
"E54000032","NHS Kent and Medway Integrated Care Board","Persons",256895,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.92,"Persons","Sex",0,126170,"To June 2023",49.31,49.11,NA
"E54000048","NHS Lancashire and South Cumbria Integrated Care Board","Persons",255000,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.05,"Persons","Sex",0,130685,"To June 2023",51.44,51.25,NA
"E54000015","NHS Leicester, Leicestershire and Rutland Integrated Care Board","Persons",153090,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.84,"Persons","Sex",0,81270,"To June 2023",53.34,53.09,NA
"E54000013","NHS Lincolnshire Integrated Care Board","Persons",123105,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.23,"Persons","Sex",0,64640,"To June 2023",52.79,52.51,NA
"E54000026","NHS Mid and South Essex Integrated Care Board","Persons",141915,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.58,"Persons","Sex",0,74985,"To June 2023",53.1,52.84,NA
"E54000022","Nhs Norfolk And Waveney Integrated Care Board","Persons",160880,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",50.29,"Persons","Sex",0,81295,"To June 2023",50.77,50.53,NA
"E54000028","NHS North Central London Integrated Care Board","Persons",157660,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.94,"Persons","Sex",0,82275,"To June 2023",52.43,52.19,NA
"E54000050","NHS North East and North Cumbria Integrated Care Board","Persons",446495,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",55.08,"Persons","Sex",0,246580,"To June 2023",55.37,55.23,NA
"E54000029","NHS North East London Integrated Care Board","Persons",221440,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",55.66,"Persons","Sex",0,123700,"To June 2023",56.07,55.86,NA
"E54000027","NHS North West London Integrated Care Board","Persons",249465,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",55.13,"Persons","Sex",0,138010,"To June 2023",55.52,55.32,NA
"E54000059","NHS Northamptonshire Integrated Care Board","Persons",96495,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",54.88,"Persons","Sex",0,53265,"To June 2023",55.51,55.2,NA
"E54000060","NHS Nottingham and Nottinghamshire Integrated Care Board","Persons",155580,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.99,"Persons","Sex",0,81280,"To June 2023",52.49,52.24,NA
"E54000011","NHS Shropshire, Telford and Wrekin Integrated Care Board","Persons",78555,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.5,"Persons","Sex",0,38375,"To June 2023",49.2,48.85,NA
"E54000038","NHS Somerset Integrated Care Board","Persons",90140,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.58,"Persons","Sex",0,42280,"To June 2023",47.23,46.9,NA
"E54000030","NHS South East London Integrated Care Board","Persons",190795,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.46,"Persons","Sex",0,92880,"To June 2023",48.9,48.68,NA
"E54000031","NHS South West London Integrated Care Board","Persons",154010,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.81,"Persons","Sex",0,75560,"To June 2023",49.31,49.06,NA
"E54000061","NHS South Yorkshire Integrated Care Board","Persons",182235,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",58.95,"Persons","Sex",0,107845,"To June 2023",59.4,59.18,NA
"E54000010","NHS Staffordshire and Stoke-on-Trent Integrated Care Board","Persons",166685,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.79,"Persons","Sex",0,88395,"To June 2023",53.27,53.03,NA
"E54000023","NHS Suffolk and North East Essex Integrated Care Board","Persons",150030,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.53,"Persons","Sex",0,74680,"To June 2023",50.03,49.78,NA
"E54000052","NHS Surrey Heartlands Integrated Care Board","Persons",115165,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.93,"Persons","Sex",0,54385,"To June 2023",47.51,47.22,NA
"E54000053","NHS Sussex Integrated Care Board","Persons",237960,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",47.95,"Persons","Sex",0,114570,"To June 2023",48.35,48.15,NA
"E54000054","NHS West Yorkshire Integrated Care Board","Persons",306635,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",55.92,"Persons","Sex",0,172020,"To June 2023",56.27,56.1,NA
"E54000040","NHS Bath and North East Somerset, Swindon and Wiltshire Integrated Care Board","Persons",124205,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",45.09,"Persons","Sex",0,56345,"To September 2023",45.64,45.36,NA
"E54000024","NHS Bedfordshire, Luton and Milton Keynes Integrated Care Board","Persons",109795,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",53.85,"Persons","Sex",0,59450,"To September 2023",54.44,54.15,NA
"E54000055","NHS Birmingham and Solihull Integrated Care Board","Persons",179470,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",56.02,"Persons","Sex",0,100960,"To September 2023",56.48,56.25,NA
"E54000062","NHS Black Country Integrated Care Board","Persons",166215,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",55.51,"Persons","Sex",0,92660,"To September 2023",55.98,55.75,NA
"E54000039","NHS Bristol, North Somerset and South Gloucestershire Integrated Care Board","Persons",117870,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.11,"Persons","Sex",0,58220,"To September 2023",49.68,49.39,NA
"E54000044","NHS Buckinghamshire, Oxfordshire and Berkshire West Integrated Care Board","Persons",214635,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.45,"Persons","Sex",0,100155,"To September 2023",46.87,46.66,NA
"E54000056","NHS Cambridgeshire and Peterborough Integrated Care Board","Persons",104195,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.94,"Persons","Sex",0,52355,"To September 2023",50.55,50.25,NA
"E54000008","NHS Cheshire and Merseyside Integrated Care Board","Persons",375980,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.56,"Persons","Sex",0,194450,"To September 2023",51.88,51.72,NA
"E54000036","NHS Cornwall and the Isles of Scilly Integrated Care Board","Persons",62365,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.18,"Persons","Sex",0,30915,"To September 2023",49.96,49.57,NA
"E54000018","NHS Coventry and Warwickshire Integrated Care Board","Persons",132095,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.54,"Persons","Sex",0,64475,"To September 2023",49.08,48.81,NA
"E54000058","NHS Derby and Derbyshire Integrated Care Board","Persons",157200,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",50.17,"Persons","Sex",0,79260,"To September 2023",50.67,50.42,NA
"E54000037","NHS Devon Integrated Care Board","Persons",145770,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",50.05,"Persons","Sex",0,73340,"To September 2023",50.57,50.31,NA
"E54000041","NHS Dorset Integrated Care Board","Persons",101305,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",47.59,"Persons","Sex",0,48525,"To September 2023",48.2,47.9,NA
"E54000034","NHS Frimley Integrated Care Board","Persons",86300,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.44,"Persons","Sex",0,44685,"To September 2023",52.11,51.78,NA
"E54000043","NHS Gloucestershire Integrated Care Board","Persons",90235,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.14,"Persons","Sex",0,43730,"To September 2023",48.79,48.46,NA
"E54000057","NHS Greater Manchester Integrated Care Board","Persons",384170,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",54.2,"Persons","Sex",0,208830,"To September 2023",54.52,54.36,NA
"E54000042","Nhs Hampshire And Isle Of Wight Integrated Care Board","Persons",227130,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",45.81,"Persons","Sex",0,104505,"To September 2023",46.22,46.01,NA
"E54000019","NHS Herefordshire and Worcestershire Integrated Care Board","Persons",128365,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.63,"Persons","Sex",0,60205,"To September 2023",47.17,46.9,NA
"E54000025","NHS Hertfordshire and West Essex Integrated Care Board","Persons",185410,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.72,"Persons","Sex",0,98175,"To September 2023",53.18,52.95,NA
"E54000051","NHS Humber and North Yorkshire Integrated Care Board","Persons",232395,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",50.79,"Persons","Sex",0,118495,"To September 2023",51.19,50.99,NA
"E54000032","NHS Kent and Medway Integrated Care Board","Persons",258935,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.69,"Persons","Sex",0,126565,"To September 2023",49.07,48.88,NA
"E54000048","NHS Lancashire and South Cumbria Integrated Care Board","Persons",256045,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",50.72,"Persons","Sex",0,130370,"To September 2023",51.11,50.92,NA
"E54000015","NHS Leicester, Leicestershire and Rutland Integrated Care Board","Persons",154020,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",53.21,"Persons","Sex",0,82335,"To September 2023",53.71,53.46,NA
"E54000013","NHS Lincolnshire Integrated Care Board","Persons",123875,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.78,"Persons","Sex",0,65730,"To September 2023",53.34,53.06,NA
"E54000026","NHS Mid and South Essex Integrated Care Board","Persons",143935,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.64,"Persons","Sex",0,76145,"To September 2023",53.16,52.9,NA
"E54000022","Nhs Norfolk And Waveney Integrated Care Board","Persons",162710,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",50.4,"Persons","Sex",0,82410,"To September 2023",50.89,50.65,NA
"E54000028","NHS North Central London Integrated Care Board","Persons",159055,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.28,"Persons","Sex",0,81945,"To September 2023",51.77,51.52,NA
"E54000050","NHS North East and North Cumbria Integrated Care Board","Persons",450215,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",55.26,"Persons","Sex",0,249455,"To September 2023",55.55,55.41,NA
"E54000029","NHS North East London Integrated Care Board","Persons",222090,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",54.86,"Persons","Sex",0,122305,"To September 2023",55.27,55.07,NA
"E54000027","NHS North West London Integrated Care Board","Persons",251315,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",54.59,"Persons","Sex",0,137680,"To September 2023",54.98,54.78,NA
"E54000059","NHS Northamptonshire Integrated Care Board","Persons",97870,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",54.94,"Persons","Sex",0,54070,"To September 2023",55.56,55.25,NA
"E54000060","NHS Nottingham and Nottinghamshire Integrated Care Board","Persons",155775,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.53,"Persons","Sex",0,82215,"To September 2023",53.03,52.78,NA
"E54000011","NHS Shropshire, Telford and Wrekin Integrated Care Board","Persons",79270,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.29,"Persons","Sex",0,38555,"To September 2023",48.98,48.64,NA
"E54000038","NHS Somerset Integrated Care Board","Persons",90270,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.44,"Persons","Sex",0,42210,"To September 2023",47.09,46.76,NA
"E54000030","NHS South East London Integrated Care Board","Persons",192695,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",47.72,"Persons","Sex",0,92375,"To September 2023",48.16,47.94,NA
"E54000031","NHS South West London Integrated Care Board","Persons",155690,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.08,"Persons","Sex",0,75245,"To September 2023",48.58,48.33,NA
"E54000061","NHS South Yorkshire Integrated Care Board","Persons",182475,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",59.28,"Persons","Sex",0,108580,"To September 2023",59.73,59.5,NA
"E54000010","NHS Staffordshire and Stoke-on-Trent Integrated Care Board","Persons",166945,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.37,"Persons","Sex",0,87830,"To September 2023",52.85,52.61,NA
"E54000023","NHS Suffolk and North East Essex Integrated Care Board","Persons",151650,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.75,"Persons","Sex",0,75825,"To September 2023",50.25,50,NA
"E54000052","NHS Surrey Heartlands Integrated Care Board","Persons",114585,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.76,"Persons","Sex",0,53915,"To September 2023",47.34,47.05,NA
"E54000053","NHS Sussex Integrated Care Board","Persons",243605,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",47.96,"Persons","Sex",0,117325,"To September 2023",48.36,48.16,NA
"E54000054","NHS West Yorkshire Integrated Care Board","Persons",309055,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",56.02,"Persons","Sex",0,173685,"To September 2023",56.37,56.2,NA
"E54000040","NHS Bath and North East Somerset, Swindon and Wiltshire Integrated Care Board","Persons",126060,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",45.96,"Persons","Sex",0,58285,"To December 2023",46.51,46.24,NA
"E54000024","NHS Bedfordshire, Luton and Milton Keynes Integrated Care Board","Persons",110140,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",54.55,"Persons","Sex",0,60405,"To December 2023",55.14,54.84,NA
"E54000055","NHS Birmingham and Solihull Integrated Care Board","Persons",181815,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",57.23,"Persons","Sex",0,104470,"To December 2023",57.69,57.46,NA
"E54000062","NHS Black Country Integrated Care Board","Persons",168505,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",56.65,"Persons","Sex",0,95850,"To December 2023",57.12,56.88,NA
"E54000039","NHS Bristol, North Somerset and South Gloucestershire Integrated Care Board","Persons",118365,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",50.9,"Persons","Sex",0,60585,"To December 2023",51.47,51.18,NA
"E54000044","NHS Buckinghamshire, Oxfordshire and Berkshire West Integrated Care Board","Persons",216775,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",47.76,"Persons","Sex",0,103980,"To December 2023",48.18,47.97,NA
"E54000056","NHS Cambridgeshire and Peterborough Integrated Care Board","Persons",105530,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.07,"Persons","Sex",0,54215,"To December 2023",51.68,51.37,NA
"E54000008","NHS Cheshire and Merseyside Integrated Care Board","Persons",378710,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.89,"Persons","Sex",0,200920,"To December 2023",53.21,53.05,NA
"E54000036","NHS Cornwall and the Isles of Scilly Integrated Care Board","Persons",64105,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",50.14,"Persons","Sex",0,32390,"To December 2023",50.91,50.52,NA
"E54000018","NHS Coventry and Warwickshire Integrated Care Board","Persons",133685,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",50.78,"Persons","Sex",0,68240,"To December 2023",51.31,51.05,NA
"E54000058","NHS Derby and Derbyshire Integrated Care Board","Persons",158930,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.09,"Persons","Sex",0,81585,"To December 2023",51.58,51.33,NA
"E54000037","NHS Devon Integrated Care Board","Persons",148745,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",50.87,"Persons","Sex",0,76045,"To December 2023",51.38,51.13,NA
"E54000041","NHS Dorset Integrated Care Board","Persons",102380,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.57,"Persons","Sex",0,50045,"To December 2023",49.19,48.88,NA
"E54000034","NHS Frimley Integrated Care Board","Persons",87140,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",53.22,"Persons","Sex",0,46670,"To December 2023",53.89,53.56,NA
"E54000043","NHS Gloucestershire Integrated Care Board","Persons",91000,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.78,"Persons","Sex",0,45595,"To December 2023",50.43,50.11,NA
"E54000057","NHS Greater Manchester Integrated Care Board","Persons",386960,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",55.51,"Persons","Sex",0,215405,"To December 2023",55.82,55.67,NA
"E54000042","Nhs Hampshire And Isle Of Wight Integrated Care Board","Persons",230215,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",46.94,"Persons","Sex",0,108520,"To December 2023",47.34,47.14,NA
"E54000019","NHS Herefordshire and Worcestershire Integrated Care Board","Persons",129300,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.68,"Persons","Sex",0,63295,"To December 2023",49.23,48.95,NA
"E54000025","NHS Hertfordshire and West Essex Integrated Care Board","Persons",187485,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",53.58,"Persons","Sex",0,100875,"To December 2023",54.03,53.81,NA
"E54000051","NHS Humber and North Yorkshire Integrated Care Board","Persons",235925,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.85,"Persons","Sex",0,122795,"To December 2023",52.25,52.05,NA
"E54000032","NHS Kent and Medway Integrated Care Board","Persons",262560,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",50.2,"Persons","Sex",0,132320,"To December 2023",50.59,50.4,NA
"E54000048","NHS Lancashire and South Cumbria Integrated Care Board","Persons",258810,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52,"Persons","Sex",0,135080,"To December 2023",52.39,52.19,NA
"E54000015","NHS Leicester, Leicestershire and Rutland Integrated Care Board","Persons",155670,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",54.22,"Persons","Sex",0,84790,"To December 2023",54.72,54.47,NA
"E54000013","NHS Lincolnshire Integrated Care Board","Persons",125295,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",53.78,"Persons","Sex",0,67725,"To December 2023",54.33,54.05,NA
"E54000026","NHS Mid and South Essex Integrated Care Board","Persons",145900,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",53.38,"Persons","Sex",0,78255,"To December 2023",53.89,53.63,NA
"E54000022","Nhs Norfolk And Waveney Integrated Care Board","Persons",165330,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",50.96,"Persons","Sex",0,84645,"To December 2023",51.44,51.2,NA
"E54000028","NHS North Central London Integrated Care Board","Persons",158785,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.18,"Persons","Sex",0,83240,"To December 2023",52.67,52.42,NA
"E54000050","NHS North East and North Cumbria Integrated Care Board","Persons",456465,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",56.37,"Persons","Sex",0,257955,"To December 2023",56.66,56.51,NA
"E54000029","NHS North East London Integrated Care Board","Persons",228490,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",56.23,"Persons","Sex",0,128945,"To December 2023",56.64,56.43,NA
"E54000027","NHS North West London Integrated Care Board","Persons",254630,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",55.47,"Persons","Sex",0,141740,"To December 2023",55.86,55.67,NA
"E54000059","NHS Northamptonshire Integrated Care Board","Persons",99095,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",55.84,"Persons","Sex",0,55635,"To December 2023",56.45,56.15,NA
"E54000060","NHS Nottingham and Nottinghamshire Integrated Care Board","Persons",158255,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",53.38,"Persons","Sex",0,84870,"To December 2023",53.87,53.63,NA
"E54000011","NHS Shropshire, Telford and Wrekin Integrated Care Board","Persons",79940,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.78,"Persons","Sex",0,40075,"To December 2023",50.48,50.13,NA
"E54000038","NHS Somerset Integrated Care Board","Persons",90415,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.05,"Persons","Sex",0,43740,"To December 2023",48.7,48.38,NA
"E54000030","NHS South East London Integrated Care Board","Persons",195510,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.94,"Persons","Sex",0,96110,"To December 2023",49.38,49.16,NA
"E54000031","NHS South West London Integrated Care Board","Persons",157940,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.18,"Persons","Sex",0,78060,"To December 2023",49.67,49.42,NA
"E54000061","NHS South Yorkshire Integrated Care Board","Persons",183855,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",60.42,"Persons","Sex",0,111505,"To December 2023",60.87,60.65,NA
"E54000010","NHS Staffordshire and Stoke-on-Trent Integrated Care Board","Persons",167585,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",53.96,"Persons","Sex",0,90820,"To December 2023",54.43,54.19,NA
"E54000023","NHS Suffolk and North East Essex Integrated Care Board","Persons",153720,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",50.43,"Persons","Sex",0,77905,"To December 2023",50.93,50.68,NA
"E54000052","NHS Surrey Heartlands Integrated Care Board","Persons",119515,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.02,"Persons","Sex",0,57725,"To December 2023",48.58,48.3,NA
"E54000053","NHS Sussex Integrated Care Board","Persons",245905,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.22,"Persons","Sex",0,121520,"To December 2023",49.61,49.42,NA
"E54000054","NHS West Yorkshire Integrated Care Board","Persons",314080,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",56.78,"Persons","Sex",0,178880,"To December 2023",57.13,56.95,NA
"E54000040","NHS Bath and North East Somerset, Swindon and Wiltshire Integrated Care Board","Persons",125035,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",48.81,"Persons","Sex",0,61375,"To March 2024",49.36,49.08,NA
"E54000024","NHS Bedfordshire, Luton and Milton Keynes Integrated Care Board","Persons",113350,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",56.38,"Persons","Sex",0,64235,"To March 2024",56.96,56.67,NA
"E54000055","NHS Birmingham and Solihull Integrated Care Board","Persons",182680,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",59.19,"Persons","Sex",0,108540,"To March 2024",59.64,59.41,NA
"E54000062","NHS Black Country Integrated Care Board","Persons",167725,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",58.85,"Persons","Sex",0,99095,"To March 2024",59.32,59.08,NA
"E54000039","NHS Bristol, North Somerset and South Gloucestershire Integrated Care Board","Persons",118995,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.97,"Persons","Sex",0,63370,"To March 2024",53.54,53.25,NA
"E54000044","NHS Buckinghamshire, Oxfordshire and Berkshire West Integrated Care Board","Persons",219050,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.93,"Persons","Sex",0,109835,"To March 2024",50.35,50.14,NA
"E54000056","NHS Cambridgeshire and Peterborough Integrated Care Board","Persons",107650,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.7,"Persons","Sex",0,57050,"To March 2024",53.29,53,NA
"E54000008","NHS Cheshire and Merseyside Integrated Care Board","Persons",380070,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",54.45,"Persons","Sex",0,207535,"To March 2024",54.76,54.6,NA
"E54000036","NHS Cornwall and the Isles of Scilly Integrated Care Board","Persons",65185,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.01,"Persons","Sex",0,34155,"To March 2024",52.78,52.39,NA
"E54000018","NHS Coventry and Warwickshire Integrated Care Board","Persons",133975,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",53.83,"Persons","Sex",0,72475,"To March 2024",54.36,54.1,NA
"E54000058","NHS Derby and Derbyshire Integrated Care Board","Persons",161255,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.62,"Persons","Sex",0,85255,"To March 2024",53.11,52.87,NA
"E54000037","NHS Devon Integrated Care Board","Persons",152805,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.26,"Persons","Sex",0,80240,"To March 2024",52.76,52.51,NA
"E54000041","NHS Dorset Integrated Care Board","Persons",103420,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.11,"Persons","Sex",0,53175,"To March 2024",51.72,51.42,NA
"E54000034","NHS Frimley Integrated Care Board","Persons",88320,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",55.13,"Persons","Sex",0,48975,"To March 2024",55.78,55.45,NA
"E54000043","NHS Gloucestershire Integrated Care Board","Persons",93515,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.19,"Persons","Sex",0,48170,"To March 2024",51.83,51.51,NA
"E54000057","NHS Greater Manchester Integrated Care Board","Persons",387345,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",57.26,"Persons","Sex",0,222380,"To March 2024",57.57,57.41,NA
"E54000042","Nhs Hampshire And Isle Of Wight Integrated Care Board","Persons",234045,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.01,"Persons","Sex",0,115175,"To March 2024",49.41,49.21,NA
"E54000019","NHS Herefordshire and Worcestershire Integrated Care Board","Persons",130730,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.21,"Persons","Sex",0,67295,"To March 2024",51.75,51.48,NA
"E54000025","NHS Hertfordshire and West Essex Integrated Care Board","Persons",189715,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",54.88,"Persons","Sex",0,104545,"To March 2024",55.33,55.11,NA
"E54000051","NHS Humber and North Yorkshire Integrated Care Board","Persons",238795,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",53.72,"Persons","Sex",0,128755,"To March 2024",54.12,53.92,NA
"E54000032","NHS Kent and Medway Integrated Care Board","Persons",264790,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.3,"Persons","Sex",0,138980,"To March 2024",52.68,52.49,NA
"E54000048","NHS Lancashire and South Cumbria Integrated Care Board","Persons",260970,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",53.34,"Persons","Sex",0,139710,"To March 2024",53.73,53.54,NA
"E54000015","NHS Leicester, Leicestershire and Rutland Integrated Care Board","Persons",157150,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",55.93,"Persons","Sex",0,88285,"To March 2024",56.43,56.18,NA
"E54000013","NHS Lincolnshire Integrated Care Board","Persons",126530,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",55.49,"Persons","Sex",0,70565,"To March 2024",56.04,55.77,NA
"E54000026","NHS Mid and South Essex Integrated Care Board","Persons",147350,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",55.13,"Persons","Sex",0,81605,"To March 2024",55.64,55.38,NA
"E54000022","Nhs Norfolk And Waveney Integrated Care Board","Persons",167345,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.38,"Persons","Sex",0,88050,"To March 2024",52.85,52.62,NA
"E54000028","NHS North Central London Integrated Care Board","Persons",161490,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",53.35,"Persons","Sex",0,86545,"To March 2024",53.83,53.59,NA
"E54000050","NHS North East and North Cumbria Integrated Care Board","Persons",460615,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",58.14,"Persons","Sex",0,268445,"To March 2024",58.42,58.28,NA
"E54000029","NHS North East London Integrated Care Board","Persons",231855,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",58.51,"Persons","Sex",0,136135,"To March 2024",58.92,58.71,NA
"E54000027","NHS North West London Integrated Care Board","Persons",256885,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",57.23,"Persons","Sex",0,147510,"To March 2024",57.61,57.42,NA
"E54000059","NHS Northamptonshire Integrated Care Board","Persons",100320,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",57.5,"Persons","Sex",0,57995,"To March 2024",58.11,57.81,NA
"E54000060","NHS Nottingham and Nottinghamshire Integrated Care Board","Persons",160195,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",54.64,"Persons","Sex",0,87930,"To March 2024",55.13,54.89,NA
"E54000011","NHS Shropshire, Telford and Wrekin Integrated Care Board","Persons",79785,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.93,"Persons","Sex",0,41710,"To March 2024",52.62,52.28,NA
"E54000038","NHS Somerset Integrated Care Board","Persons",91090,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.72,"Persons","Sex",0,45585,"To March 2024",50.37,50.04,NA
"E54000030","NHS South East London Integrated Care Board","Persons",195865,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.28,"Persons","Sex",0,100870,"To March 2024",51.72,51.5,NA
"E54000031","NHS South West London Integrated Care Board","Persons",158670,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.15,"Persons","Sex",0,81545,"To March 2024",51.64,51.39,NA
"E54000061","NHS South Yorkshire Integrated Care Board","Persons",184570,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",61.99,"Persons","Sex",0,114825,"To March 2024",62.43,62.21,NA
"E54000010","NHS Staffordshire and Stoke-on-Trent Integrated Care Board","Persons",167590,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",55.55,"Persons","Sex",0,93490,"To March 2024",56.02,55.78,NA
"E54000023","NHS Suffolk and North East Essex Integrated Care Board","Persons",154795,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.11,"Persons","Sex",0,81045,"To March 2024",52.61,52.36,NA
"E54000052","NHS Surrey Heartlands Integrated Care Board","Persons",121025,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.93,"Persons","Sex",0,60775,"To March 2024",50.5,50.22,NA
"E54000053","NHS Sussex Integrated Care Board","Persons",248395,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.22,"Persons","Sex",0,127715,"To March 2024",51.61,51.42,NA
"E54000054","NHS West Yorkshire Integrated Care Board","Persons",317795,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",58.28,"Persons","Sex",0,185745,"To March 2024",58.62,58.45,NA
"E54000040","NHS Bath and North East Somerset, Swindon and Wiltshire Integrated Care Board","Persons",137295,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",53.4,"Persons","Sex",0,73670,"To June 2024",53.92,53.66,NA
"E54000024","NHS Bedfordshire, Luton and Milton Keynes Integrated Care Board","Persons",121885,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",55.48,"Persons","Sex",0,67965,"To June 2024",56.04,55.76,NA
"E54000055","NHS Birmingham and Solihull Integrated Care Board","Persons",189465,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",58.84,"Persons","Sex",0,111895,"To June 2024",59.28,59.06,NA
"E54000062","NHS Black Country Integrated Care Board","Persons",173835,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",58.49,"Persons","Sex",0,102070,"To June 2024",58.95,58.72,NA
"E54000039","NHS Bristol, North Somerset and South Gloucestershire Integrated Care Board","Persons",120195,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",53.64,"Persons","Sex",0,64815,"To June 2024",54.21,53.92,NA
"E54000044","NHS Buckinghamshire, Oxfordshire and Berkshire West Integrated Care Board","Persons",222970,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",50.5,"Persons","Sex",0,113075,"To June 2024",50.92,50.71,NA
"E54000056","NHS Cambridgeshire and Peterborough Integrated Care Board","Persons",118840,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.19,"Persons","Sex",0,62355,"To June 2024",52.75,52.47,NA
"E54000008","NHS Cheshire and Merseyside Integrated Care Board","Persons",384575,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",54.97,"Persons","Sex",0,212015,"To June 2024",55.29,55.13,NA
"E54000036","NHS Cornwall and the Isles of Scilly Integrated Care Board","Persons",69925,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.34,"Persons","Sex",0,36860,"To June 2024",53.08,52.71,NA
"E54000018","NHS Coventry and Warwickshire Integrated Care Board","Persons",134940,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",54.34,"Persons","Sex",0,73685,"To June 2024",54.87,54.61,NA
"E54000058","NHS Derby and Derbyshire Integrated Care Board","Persons",171105,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.3,"Persons","Sex",0,89895,"To June 2024",52.78,52.54,NA
"E54000037","NHS Devon Integrated Care Board","Persons",158700,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.58,"Persons","Sex",0,83835,"To June 2024",53.07,52.83,NA
"E54000041","NHS Dorset Integrated Care Board","Persons",115340,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",50.24,"Persons","Sex",0,58275,"To June 2024",50.81,50.52,NA
"E54000034","NHS Frimley Integrated Care Board","Persons",90195,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",55.6,"Persons","Sex",0,50440,"To June 2024",56.25,55.92,NA
"E54000043","NHS Gloucestershire Integrated Care Board","Persons",99755,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.42,"Persons","Sex",0,51605,"To June 2024",52.04,51.73,NA
"E54000057","NHS Greater Manchester Integrated Care Board","Persons",394100,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",57.48,"Persons","Sex",0,227135,"To June 2024",57.79,57.63,NA
"E54000042","Nhs Hampshire And Isle Of Wight Integrated Care Board","Persons",245655,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",49.27,"Persons","Sex",0,121510,"To June 2024",49.66,49.46,NA
"E54000019","NHS Herefordshire and Worcestershire Integrated Care Board","Persons",133410,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.91,"Persons","Sex",0,69605,"To June 2024",52.44,52.17,NA
"E54000025","NHS Hertfordshire and West Essex Integrated Care Board","Persons",197970,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",54.88,"Persons","Sex",0,109090,"To June 2024",55.32,55.1,NA
"E54000051","NHS Humber and North Yorkshire Integrated Care Board","Persons",255830,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",53.74,"Persons","Sex",0,137970,"To June 2024",54.12,53.93,NA
"E54000032","NHS Kent and Medway Integrated Care Board","Persons",268310,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",53.04,"Persons","Sex",0,142825,"To June 2024",53.42,53.23,NA
"E54000048","NHS Lancashire and South Cumbria Integrated Care Board","Persons",265070,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",53.72,"Persons","Sex",0,142905,"To June 2024",54.1,53.91,NA
"E54000015","NHS Leicester, Leicestershire and Rutland Integrated Care Board","Persons",168090,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",56.11,"Persons","Sex",0,94720,"To June 2024",56.59,56.35,NA
"E54000013","NHS Lincolnshire Integrated Care Board","Persons",135680,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",55.6,"Persons","Sex",0,75795,"To June 2024",56.13,55.86,NA
"E54000026","NHS Mid and South Essex Integrated Care Board","Persons",162075,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",54.42,"Persons","Sex",0,88600,"To June 2024",54.91,54.67,NA
"E54000022","Nhs Norfolk And Waveney Integrated Care Board","Persons",179900,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.56,"Persons","Sex",0,94975,"To June 2024",53.02,52.79,NA
"E54000028","NHS North Central London Integrated Care Board","Persons",161825,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",53.39,"Persons","Sex",0,86790,"To June 2024",53.87,53.63,NA
"E54000050","NHS North East and North Cumbria Integrated Care Board","Persons",477970,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",58.48,"Persons","Sex",0,280165,"To June 2024",58.75,58.62,NA
"E54000029","NHS North East London Integrated Care Board","Persons",233845,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",57.62,"Persons","Sex",0,135205,"To June 2024",58.02,57.82,NA
"E54000027","NHS North West London Integrated Care Board","Persons",265495,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",57.31,"Persons","Sex",0,152645,"To June 2024",57.68,57.49,NA
"E54000059","NHS Northamptonshire Integrated Care Board","Persons",106030,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",57.2,"Persons","Sex",0,60965,"To June 2024",57.79,57.5,NA
"E54000060","NHS Nottingham and Nottinghamshire Integrated Care Board","Persons",172165,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",54.71,"Persons","Sex",0,94590,"To June 2024",55.18,54.94,NA
"E54000011","NHS Shropshire, Telford and Wrekin Integrated Care Board","Persons",81410,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",52.63,"Persons","Sex",0,43125,"To June 2024",53.32,52.97,NA
"E54000038","NHS Somerset Integrated Care Board","Persons",90840,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",50.38,"Persons","Sex",0,46065,"To June 2024",51.03,50.71,NA
"E54000030","NHS South East London Integrated Care Board","Persons",200225,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.36,"Persons","Sex",0,103275,"To June 2024",51.8,51.58,NA
"E54000031","NHS South West London Integrated Care Board","Persons",160510,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.31,"Persons","Sex",0,82755,"To June 2024",51.8,51.56,NA
"E54000061","NHS South Yorkshire Integrated Care Board","Persons",192750,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",61.84,"Persons","Sex",0,119615,"To June 2024",62.27,62.06,NA
"E54000010","NHS Staffordshire and Stoke-on-Trent Integrated Care Board","Persons",171390,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",56.06,"Persons","Sex",0,96475,"To June 2024",56.52,56.29,NA
"E54000023","NHS Suffolk and North East Essex Integrated Care Board","Persons",167175,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.84,"Persons","Sex",0,87055,"To June 2024",52.31,52.07,NA
"E54000052","NHS Surrey Heartlands Integrated Care Board","Persons",124105,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",50.41,"Persons","Sex",0,62910,"To June 2024",50.97,50.69,NA
"E54000053","NHS Sussex Integrated Care Board","Persons",260845,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",51.39,"Persons","Sex",0,134545,"To June 2024",51.77,51.58,NA
"E54000054","NHS West Yorkshire Integrated Care Board","Persons",337245,NA,NA,"CVDP008CHOL","Patients with no GP recorded CVD and either a GP recorded QRISK score of 10% or more, or CKD and diabetes, who are currently treated with lipid lowering therapy.","Cholesterol: Primary prevention of CVD treated with LLT (CVDP008CHOL)",57.9,"Persons","Sex",0,195835,"To June 2024",58.23,58.07,NA
